



Biocept Inc.
Investor Relations Department
5810 Nancy Ridge Drive
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: BIOC

Last Trade:	1.19
Trade Time:	3:59 PM ET Aug 16, 2017
Change:	-0.07 (-5.200%)
Day Range	1.17 - 1.25
52-Week Range	0.74 - 3.39
Volume	418,214

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 14, 2017*
[Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR](#)
- Aug 10, 2017*
[Biocept Reports Second Quarter 2017 Financial Results](#)
- Aug 10, 2017*
[Biocept Announces Private Placement of \\$2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund](#)
- Aug 7, 2017*
[Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform](#)
- Aug 3, 2017*
[Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 30, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 10, 2016*
[Quarterly Report \(10-Q\)](#)